Investing.com - Le azioni di Madrigal Pharmaceuticals (NASDAQ: MDGL) sono scese del 4% nelle contrattazioni pre-market di ...

A Montgomery County pharmaceutical company is taking its shot at succeeding where many other drug developers have previously failed in what is projected to be a multibillion-dollar market opportunity.

In its first full quarter on the market, Madrigal's Rezdiffra had sales of $14.6 million. Despite the strong start, the company's shares dropped 13% ...

That’s exactly what happened Friday morning when the markets opened—at least for Madrigal, which jumped more than 16% to $283.55. Other companies in the space had more modest bumps, such as ...

Financial Health Madrigal remains well-funded early on in Rezdiffra's launch. As of March 31, their cash and cash equivalents were $622.517 million. Marketable securities stood at $436.546 million.